Predictive Oncology (NASDAQ:POAI) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of Predictive Oncology (NASDAQ:POAI) to a strong sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Predictive Oncology in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Predictive Oncology has a consensus rating of “Sell”.

Predictive Oncology Stock Up 15.0%

NASDAQ POAI opened at $4.90 on Friday. The stock has a market capitalization of $16.61 million, a P/E ratio of -0.36 and a beta of 1.36. Predictive Oncology has a 52-week low of $3.88 and a 52-week high of $45.90. The firm has a 50-day moving average price of $8.75 and a 200 day moving average price of $11.72.

Predictive Oncology (NASDAQ:POAI) last released its earnings results on Friday, November 14th. The medical instruments supplier reported ($4.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($3.17). The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $1.50 million. Predictive Oncology had a negative return on equity of 732.73% and a negative net margin of 5,065.23%. On average, equities research analysts expect that Predictive Oncology will post -2.08 earnings per share for the current fiscal year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.